The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24020966 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shihoko Komine-Aizawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Tokyo 173-8610, Japan. Hauptthemen laut MEDLINE: Mycobacterium bovis, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Nihon University Research Grant for 2022, Nihon University Multidisciplinary Research Grant for 2016.
Abstract (Originalsprache)
Mycobacterium tuberculosis (Mtb) infection remains a major health problem worldwide. Although the Bacillus Calmette-Guérin (BCG) vaccine is the most widely used vaccination for preventing tuberculosis (TB), its efficacy is limited. We previously developed a new recombinant BCG (rBCG)-based vaccine encoding the Ag85B protein of M. kansasii (Mkan85B), termed rBCG-Mkan85B, and its administration is followed by boosting with plasmid DNA expressing the Ag85B gene (DNA-Mkan85B). Previously, we identified MHC-I (H2-Kd)-restricted epitopes that highly cross-react with those of Mtb in BALB/c (H2d) and CB6F1 (H2b/d) mice. We also reported that the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination protocol protected CB6F1 mice against M. kansasii infection. In this study, to investigate the protective effect of our novel rBCG against Mtb infection, CB6F1 mice were either left unimmunized or immunized with the BCG, rBCG-Mkan85B, or rBCG-Mkan85B/DNA-Mkan85B vaccine for 10 weeks prior to inhalation exposure to the virulent Mtb Erdman strain for another 6 weeks. Compared with the BCG and rBCG-Mkan85B vaccinations, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination protocol significantly reduced the numbers of pulmonary colony-forming units (CFUs). Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination induced antigen-specific polyfunctional CD4+ and CD8+ T cells. These results suggest that CD8+ T-cell immunity to immunodominant epitopes of Mtb is enhanced by rBCG vector-based immunization. Thus, rBCG vector-based vaccinations may overcome the limited ability of the current BCG vaccine to elicit TB immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Tokyo 173-8610, Japan.
- Japan BCG Laboratory, 3-1-5 Matsuyama, Tokyo 204-0022, Japan.
ORCID-Profile: Shihoko Komine-Aizawa, Satoshi Hayakawa
Förderung
- JSPS KAKENHI
- Nihon University Research Grant for 2022
- Nihon University Multidisciplinary Research Grant for 2016
Zitieren
APA
Komine-Aizawa, S., Mizuno, S., Kawano, A., Hayakawa, S., Matsuo, K., & Honda, M. (2023). The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24020966
Vancouver
Komine-Aizawa S, Mizuno S, Kawano A, Hayakawa S, Matsuo K, Honda M. The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24020966
BibTeX
@article{KomineAizawa2023,
author = {Komine-Aizawa, Shihoko and Mizuno, Satoru and Kawano, Akira and Hayakawa, Satoshi and Matsuo, Kazuhiro and Honda, Mitsuo},
title = {The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24020966}
}
EUVIMED